Free tool
FAERS Monitor: Oraqix
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 021451 or its brand name (Oraqix, Lidocaine, Prilocaine). Reports on generic versions are filed under their own applications.
Reports
1,450
Serious
825
57% of reports
Hospitalization
456
Death reported
130
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- fatigue160
- nausea131
- diarrhoea110
- off label use99
- vomiting85
- dyspnoea74
- pyrexia73
- product dose omission issue72
- death69
- headache69
- dizziness68
- pain66
- pneumonia65
- cough63
- drug ineffective58
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 2 |
| 2005 | 1 |
| 2006 | 4 |
| 2007 | 1 |
| 2008 | 1 |
| 2009 | 2 |
| 2010 | 6 |
| 2011 | 3 |
| 2012 | 3 |
| 2013 | 12 |
| 2014 | 14 |
| 2015 | 32 |
| 2016 | 44 |
| 2017 | 56 |
| 2018 | 96 |
| 2019 | 129 |
| 2020 | 110 |
| 2021 | 98 |
| 2022 | 129 |
| 2023 | 144 |
| 2024 | 152 |
| 2025 | 226 |
| 2026 | 185 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,052,709 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| product dose omission issueSignal | 72 | 3.6 | 2.8 | 131 |
| coughSignal | 63 | 3.3 | 2.6 | 98 |
| pyrexiaSignal | 73 | 3.1 | 2.4 | 101 |
| fatigueSignal | 160 | 3.0 | 2.6 | 217 |
| pneumoniaSignal | 65 | 2.9 | 2.3 | 81 |
| vomitingSignal | 85 | 2.6 | 2.1 | 86 |
| diarrhoeaSignal | 110 | 2.5 | 2.1 | 98 |
| nauseaSignal | 131 | 2.4 | 2.0 | 110 |
| dizziness | 68 | 2.0 | 1.6 | 33 |
| dyspnoea | 74 | 1.9 | 1.5 | 31 |
| off label use | 99 | 1.6 | 1.4 | 25 |
| headache | 69 | 1.6 | 1.3 | 15 |
| pain | 66 | 1.6 | 1.2 | 13 |
| death | 69 | 1.2 | 0.9 | 1 |
| drug ineffective | 58 | 0.6 | 0.5 | 12 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.